We are an early developmental stage biotechnology company engaged in the
discovery, development and commercialization of new classes of broad spectrum
antibiotics for gram-negative and gram-positive bacterial infections, including
some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called
Our drug discovery platform currently provides a multi-pronged level understanding of interactions between drug candidates and their bacterial targets and enables us to engineer antibiotics with enhanced characteristics to attack a Drug Resistant Bacteria with a multi-targeted approach. The Company plans on developing eight pharmaceutical compounds. Our drug candidates are in the development stage. Our pharmaceutical compounds originated at Kard Scientific, Inc., a preclinical contract research organization founded by our President Rajah Menon in 2002 and of which Mr. Menon is its principal shareholder. These compounds were composed and formulated by researchers at Kard who then conducted in-vitro studies. On October 3, 2013, Kard and Mr. Menon assigned all of their rights, formulations, and all studies and data related to efflux pump antibiotics to the Company. The candidates have only been studied in cell-based assays (in-vitro), but have not been studied in small animals (in-vivo) or animals with drug resistant bacteria for efficacy, efficiency and toxicity. We currently own all development and marketing rights to our products. We plan on contracting research and development of our technologies to third parties. The Company intends to file patent applications for each of these candidates as studies advance and funds become available. The Company has assigned a priority to the development of NEB-MRSA and NA-MRSA and has designated these as our leading drug candidates.